BRUCE JAY LEVINE
Medical Practice in Cherry Hill, NJ
License number
Pennsylvania MD030007E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Cherry Hill, NJ 08003
Pennsylvania
Pennsylvania
Personal information
See more information about BRUCE JAY LEVINE at radaris.comName
Address
Phone
5543 Fair Oaks St, Pittsburgh, PA 15217
53 Fredericks St, West Orange, NJ 07052
4000 Presidential Blvd APT 814, Philadelphia, PA 19131
647 Chelten Hills Dr, Elkins Park, PA 19027
68 Cameo Dr, Cherry Hill, NJ 08003
Professional information
Methods Of Generating Human Cd4+ Th1 Cells
US Patent:
2004024, Dec 2, 2004
Filed:
Feb 27, 2004
Appl. No.:
10/488196
Inventors:
Daniel Fowler - Bethesda MD, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
International Classification:
A61K045/00, C12N005/08
US Classification:
424/093710, 435/372000
Abstract:
Methods are provided for producing a population of substantially purified CD4+ Th1 lymphocytes. The method includes stimulating a population of substantially purified CD4+ T cells isolated from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Th1 supportive environment to form a stimulated population of T cells. The stimulated population of CD4+ T cells is allowed to proliferate in a Th1 supportive environment. In one example, the Th1 supportive environment includes at least 20 IU/ml of IL-2, for example about 1000 I.U./ml of IL-2, and a neutralizing amount of an IL-4, an IL-13, and/or an IL-4/IL-13 neutralizing agent. In other examples, the supportive environment further includes at least 1 ng/ml of IL-12, for example about 2.5 ng/ml of IL-12. Purified populations of Th1 cells are disclosed herein, as are methods for their use.
Regulatory T Cells And Their Use In Immunotherapy And Suppression Of Autoimmune Responses
US Patent:
7651855, Jan 26, 2010
Filed:
Apr 19, 2004
Appl. No.:
10/827023
Inventors:
Bruce Blazar - Golden Valley MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Birchwood MN, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Carl June - Merion Station PA, US
Wayne R. Godfrey - Birchwood MN, US
Richard G. Carroll - Lansdowne PA, US
Bruce Levine - Cherry Hill NJ, US
James L. Riley - Downingtown PA, US
Patricia Taylor - St. Paul MN, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
C12N 5/00
US Classification:
435375, 435373
Abstract:
Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4CD25 suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.
Use Of Chimeric Antigen Receptor-Modified T-Cells To Treat Cancer
US Patent:
2013028, Oct 31, 2013
Filed:
Dec 9, 2011
Appl. No.:
13/992622
Inventors:
Carl H. June - Merion Station PA, US
Bruce L. Levine - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
Bruce L. Levine - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 35/14
US Classification:
424 9321, 536 234, 5303873, 435328, 4353201
Abstract:
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Methods Of Generating Human Cd4+ Th2 Cells And Uses Thereof
US Patent:
2004017, Sep 9, 2004
Filed:
Dec 23, 2003
Appl. No.:
10/481913
Inventors:
Daniel Fowler - Bethesda MD, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Michael Bishop - Rockville MD, US
Carl June - Merion Station PA, US
Bruce Levine - Cherry Hill NJ, US
Jeanne Hou - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald Gress - Gaithersburg MD, US
Michael Bishop - Rockville MD, US
Carl June - Merion Station PA, US
Bruce Levine - Cherry Hill NJ, US
International Classification:
A61K039/395, C12N005/08
US Classification:
435/372000, 424/144100
Abstract:
A method is provided for producing a population of substantially purified CD4 Th2 lymphocytes. The method includes stimulating a population of substantially purified CD4 T cells isolated from a subject by contacting the population with an immobilized anti-CD3 monoclonal antibody and an immobilized antibody that specifically binds to a T cell costimulatory molecule in the presence of a Th2 supportive environment to form a stimulated population of T cells. Purified populations of Th2 cells are disclosed herein, as are methods for their use. For example, substantially purified CD4 Th2 lymphocytes can be used to treat graft-versus-host-disease, tumors, and autoimmune disorders.
Compositions For Treatment Of Cancer
US Patent:
2013028, Oct 31, 2013
Filed:
Jul 10, 2013
Appl. No.:
13/938923
Inventors:
Bruce L. Levine - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
International Classification:
A61K 35/14
US Classification:
4353723
Abstract:
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Rapamycin-Resistant T Cells And Therapeutic Uses Thereof
US Patent:
7718196, May 18, 2010
Filed:
Dec 9, 2005
Appl. No.:
11/298313
Inventors:
Daniel H. Fowler - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald E. Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
Unsu Jung - Ashburn VA, US
Ronald E. Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
Assignee:
The United States of America, as represented by the Department of Health and Human Services - Washington DC
The Trustees of the University of Pennsylvania - Philadelphia PA
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 35/28, C12N 5/08
US Classification:
424578, 4353723
Abstract:
Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.
Generation Of Use Of Tc1 And Tc2 Cells
US Patent:
2004025, Dec 23, 2004
Filed:
Apr 29, 2004
Appl. No.:
10/494540
Inventors:
Daniel Fowler - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Jeffrey Medin - North York, CA
Ronald Gress - Gaithersburg MD, US
Andreas Erdmann - Washington DC, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
Unsu Jung - Ashburn VA, US
Jeffrey Medin - North York, CA
Ronald Gress - Gaithersburg MD, US
Andreas Erdmann - Washington DC, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
International Classification:
A61K045/00, A61K038/20
US Classification:
424/085200, 424/093710
Abstract:
A method is provided for producing a population of CD8 Tc1 and/or Tc2 lymphocytes ex vivo. The method includes stimulating a population of T cells obtained from a subject by contacting the population with an anti-CD3 monoclonal antibody and an antibody that specifically binds to a T cell costimulatory molecule in the presence of a Tc1 or Tc2 supportive environment to form a stimulated population of T cells. The stimulated population of CD8 T cells is allowed to proliferate in a Tc1 or Tc2 supportive environment. Purified populations of Tc1 and Tc2 cells are disclosed herein, as are methods for their use.
Methods For Treatment Of Cancer
US Patent:
2013030, Nov 21, 2013
Filed:
Jul 10, 2013
Appl. No.:
13/938947
Inventors:
Bruce L. Levine - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
David L. Porter - Springfield PA, US
Michael D. Kalos - Philadelphia PA, US
Michael C. Milone - Cherry Hill NJ, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 35/14
US Classification:
4241841
Abstract:
The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Methods For Downregulating Ccr5 In T Cells With Anti-Cd3 Antibodies And Anti-Cd28 Antibodies
US Patent:
7927595, Apr 19, 2011
Filed:
Feb 20, 1998
Appl. No.:
09/027205
Inventors:
Carl H. June - Rockville MD, US
Richard G. Carroll - Gaithersburg MD, US
James L. Riley - Elkridge MD, US
Daniel C. St. Louis - Rockville MD, US
Bruce L. Levine - Cherry Hill NJ, US
Richard G. Carroll - Gaithersburg MD, US
James L. Riley - Elkridge MD, US
Daniel C. St. Louis - Rockville MD, US
Bruce L. Levine - Cherry Hill NJ, US
Assignee:
The United States of America as represented by the Secretary of the Navy - Washington DC
International Classification:
A61K 39/395, C07K 16/28
US Classification:
4241541, 4241301, 4241431, 4241441, 4241531, 4241731, 5303871, 5303881, 5303882, 5303887, 53038875
Abstract:
Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.
Rapamycin-Resistant T Cells And Therapeutic Uses Thereof
US Patent:
8075921, Dec 13, 2011
Filed:
Mar 30, 2010
Appl. No.:
12/750374
Inventors:
Daniel H. Fowler - Bethesda MD, US
Unsu Jung - Ashburn VA, US
Ronald E. Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
Unsu Jung - Ashburn VA, US
Ronald E. Gress - Gaithersburg MD, US
Bruce Levine - Cherry Hill NJ, US
Carl June - Merion Station PA, US
Assignee:
The United States of America as represented by the Secretary of the Deparment of Health and Human Services - Washington DC
The Trustees of the University of Pennsylvania - Philadelphia PA
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 35/28
US Classification:
424577
Abstract:
Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer.